CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño‐Tarragona, Nicholas C.P. Cross, Juan Carlos Hernández‐Boluda et al.|Blood Advances|2023Cited by 32
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemiaGonzalo Carreño‐Tarragona, On behalf of the MPN Spanish Group (GEMFIN), Rodrigo Gil-Manso et al.|Leukemia|2026Cited by 0